NCT03204929View on ClinicalTrials.gov

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

November 30, 2019

Study Completion Date

February 29, 2020

Conditions
Parkinson Disease
Interventions
DRUG

Cu(II)ATSM

copper-containing synthetic small molecule

Trial Locations (2)

2109

Macquarie University, Macquarie Park

3050

The Royal Melbourne Hospital, Melbourne

Sponsors
All Listed Sponsors
lead

Collaborative Medicinal Development Pty Limited

INDUSTRY

NCT03204929 - Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease | Biotech Hunter | Biotech Hunter